Technology Networks spoke with ACD/Labs’ Andrew Anderson about how the field of biochemical research is being changed by automation and how our new product, Katalyst D2D, hopes to speed up pharmaceutical development.
Technology Networks spoke with ACD/Labs’ Andrew Anderson about how the field of biochemical research is being changed by automation and how our new product, Katalyst D2D, hopes to speed up pharmaceutical development.